Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$0.48 - $1.02 $24,192 - $51,410
-50,402 Reduced 4.88%
982,743 $569,000
Q4 2022

Feb 14, 2023

SELL
$0.8 - $1.0 $26,293 - $32,867
-32,867 Reduced 3.08%
1,033,145 $836,000
Q3 2022

Nov 10, 2022

SELL
$0.94 - $1.23 $61,089 - $79,936
-64,989 Reduced 5.75%
1,066,012 $981,000
Q2 2022

Aug 15, 2022

SELL
$1.1 - $2.23 $46,377 - $94,019
-42,161 Reduced 3.59%
1,131,001 $1.29 Million
Q1 2022

May 13, 2022

SELL
$1.72 - $2.96 $161,451 - $277,846
-93,867 Reduced 7.41%
1,173,162 $2.49 Million
Q4 2021

Feb 14, 2022

BUY
$2.35 - $9.95 $2.7 Million - $11.4 Million
1,148,508 Added 969.03%
1,267,029 $3.67 Million
Q3 2021

Nov 15, 2021

SELL
$9.31 - $13.25 $60,319 - $85,846
-6,479 Reduced 5.18%
118,521 $1.16 Million
Q1 2021

May 14, 2021

BUY
$15.01 - $25.74 $1.88 Million - $3.22 Million
125,000 New
125,000 $2.26 Million

About Angion Biomedica Corp.


  • Ticker ANGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,113,300
  • Description
  • Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primaril...
More about ANGN
Track This Portfolio

Track Nantahala Capital Management, LLC Portfolio

Follow Nantahala Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nantahala Capital Management, LLC with notifications on news.